Dupixent CTCL MDL: what the October 1 conference may decide
Dupixent CTCL MDL: what the October 1 conference may decide
Last reviewed: September 18, 2026
A first court conference can sound bigger than it is. For families dealing with CTCL after Dupixent, it is important to keep the October 1 date in the right box: useful, but not decisive.
The federal cases were moved into one court on June 4, 2026. The Judicial Panel on Multidistrict Litigation sent the Dupixent CTCL lawsuits to the District of New Jersey, where Judge Zahid N. Quraishi is overseeing MDL No. 3180. The transfer order said the cases overlap on three basic questions: what the science shows, when Sanofi and Regeneron allegedly knew about any risk, and whether the warnings were enough.
That is a starting point, not an ending. The reported October 1, 2026 initial case-management conference should help the judge and lawyers decide how the case will be run. It will not decide causation. It will not announce a settlement. It will not tell any family what their claim is worth.
For the broader background, see our Dupixent lawsuit hub. We also keep a plain list of the matters we are following on our current mass torts page.
What the first conference may cover
Early MDL conferences are usually about housekeeping, but the housekeeping matters. A court has to decide who speaks for plaintiffs on shared issues, how filings should be organized, how often the parties should report back, and what needs to happen before discovery starts moving.
In practical terms, families should watch for orders about:
- plaintiff leadership;
- a master complaint or short-form complaint;
- preservation of company, pharmacy, and medical records;
- discovery timing;
- future status conferences;
- how new federal cases will be transferred into MDL 3180.
Those items sound dry. They are also how a new MDL begins to turn from scattered lawsuits into one managed proceeding.
Why medical records still matter more than court headlines
The legal fight is not just “Dupixent versus CTCL.” The hard question is timing.
CTCL can look like eczema or stubborn dermatitis, especially early in the disease. Some complaints allege Dupixent caused CTCL. Some allege it accelerated a lymphoma that was already present. Others focus on delayed diagnosis or unmasking, where the cancer may have been mistaken for a skin condition before it was finally biopsied and named.
That is why a clean timeline helps. A reviewer will want dates: when the skin symptoms began, when Dupixent started, whether symptoms improved and then changed, when biopsies were done, and when CTCL, mycosis fungoides, or Sézary syndrome was confirmed.
If you are gathering records, do not try to write a legal brief. A one-page timeline in normal language is often more useful.
What the sources say right now
The public record is still cautious. The JPML order says the cases share common factual questions. It does not rule that Dupixent caused anyone’s cancer.
The current DailyMed prescribing information for Dupixent lists the drug’s approved uses and warnings. It does not present the MDL allegations as an established medical conclusion.
The studies are part of the reason these claims are being investigated, but they also show why the fight is not simple. A 2024 Journal of the American Academy of Dermatology study reported a higher CTCL risk in atopic dermatitis patients who used dupilumab, while noting that an association does not prove causation. A 2025 European Respiratory Journal asthma study reported higher lymphoma risk in dupilumab-treated asthma patients, especially T-cell and NK-cell lymphomas; the same abstract also reported lower all-cause mortality in the dupilumab group.
That mixed picture is the courtroom problem. Plaintiffs will look for warning evidence and company documents. Defendants are expected to dispute causation and emphasize that early CTCL can be mistaken for eczema before a patient ever receives Dupixent.
What families can do now
If Dupixent use came before a CTCL diagnosis, the most useful step is to preserve the paper trail.
Start with pharmacy records and prescription history. Write down the first injection date, dose, prescribing doctor, stop date, and any gaps in treatment. Then gather dermatology records from before and during Dupixent use. Biopsy and pathology reports matter most, including older biopsies that were negative, unclear, or later reviewed again.
Oncology records help show treatment and severity. Dated photos can help if they already exist. Do not edit or stage anything.
To learn who reviews claims for Mass Tort America, visit our about page. To reach us, use the contact options on Mass Tort America.
FAQ
Does the October 1 conference mean there is a settlement?
No. It is an organizing conference. It does not decide liability, create a fund, or value anyone’s claim.
Is the Dupixent CTCL MDL a class action?
No. An MDL coordinates related federal lawsuits for pretrial work. Each plaintiff keeps an individual case.
Which injuries are central to MDL 3180?
The current federal MDL focuses on cutaneous T-cell lymphoma and CTCL subtypes. The JPML left questions about other T-cell lymphomas for later transfer decisions.
Should I stop taking Dupixent because lawsuits were filed?
No. Talk to your treating doctor before stopping or changing any prescription.
Sources
- JPML Transfer Order, MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation: https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3180-Transfer_Order-5-26.pdf
- AboutLawsuits, “Dupixent MDL Judge To Meet With Lawyers for Initial Case Management Conference in October 2026”: https://www.aboutlawsuits.com/dupixent-lawsuit/dupixent-mdl-judge-initial-case-management-conference-october-2026/
- DailyMed, Dupixent prescribing information, revised April 2026: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780
- Hasan et al., Journal of the American Academy of Dermatology, PubMed abstract: https://pubmed.ncbi.nlm.nih.gov/38588818/
- Ma et al., European Respiratory Journal, PubMed abstract: https://pubmed.ncbi.nlm.nih.gov/40537179/
This article is attorney advertising and is for informational purposes only. It is not medical advice and does not create an attorney-client relationship. Past results do not guarantee future outcomes.
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →